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Abstract
Major Depressive Disorder (MDD) is a debilitating mental disorder that 
can severely impair and individual’s ability to lead a normal life. 
Conventional therapies available to treat MDD include cognitive-
behavioral therapy, selective serotonin reuptake inhibitors, selective-
norepinephrine reuptake inhibitors, tricyclic antidepressants, and 
monoamine oxidase inhibitors. Many patients with MDD do not respond to 
conventional antidepressant treatments and have what is termed 
treatment-resistant depression. This review analyzes the use of 
psychedelics (I), including ketamine and psilocybin, in the treatment of 
depressive symptoms (O) in patients with MDD (P) compared to 
conventional antidepressant treatments (C).
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Published within the last 10 years
Exclusion Criteria:
Systematic review or meta-analysis
 Involvement of animal test subjects over humans
Most of these studies found that when using psychedelics, compared to a 
placebo, there was a significant reduction in depressive symptoms. There 
were also noticeable deficits in some of the studies, including limited 
participant demographics, total duration, and study design. As a results, 
the safety and efficacy of psychedelic therapy as an alternative to 
standard antidepressant treatment cannot be confirmed and further study 
on this topic is warranted.
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References:
1.Major Depression. National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/major-depression.shtml. Accessed April 8, 2020.
2.Duval F, Lebowitz BD, Macher JP. Treatments in depression. Dialogues Clin Neurosci. 2006;8(2):191–206.
3.Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatric 
Disease & Treatment. 2020;16:221-234. Doi10.2147/NDT.S198774
4.Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-
up. Psychopharmacology. 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x.
5.Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with 
life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. doi:10.1177/0269881116675512
6.Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with 
life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. doi:10.1177/0269881116675513
7.Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and 
PTSD: a retrospective study. Psychopharmacology. 2018;235(2):393-398. doi:10.1007/s00213-017-4786-3.
8.Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA. A single infusion of ketamine improves depression scores in patients with 
anxious bipolar depression. Bipolar Disorders. 2015;17(4):438-443. doi:10.1111/bdi.12277.
9.Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a 
randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663. Doi:10.1017/S0033291718001356
10.Lapidus KAB, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry. 
2014;76(12):970-976. doi:10.1016/j.biopsych.2014.03.026.
Efficacy of Psychedelics in the Treatment of 
Major Depressive Disorder
There is evidence that encourages the pursuit of more data on the efficacy 
of psychedelics as an alternative MDD treatment. There were many 
positive findings documented in these studies, however there is not 
enough evidence to justify a change in standard antidepressant treatment 
practices for the general population. For patients dealing with treatment-
resistant depression, it appears that psychedelics are a safe alternative to 
try that has shown positive results to a small sample population. 
Future research should focus on recruiting a larger, more diverse 
population sample as that would yield more results across multiple racial 
groups, and socioeconomic backgrounds which would allow for better 
generalization of research results.
Conclusion
ketamine (Ionescu et al). Overall, many of the studies showed 
There is evidence that suggests psychedelic therapy may be 
controlling depressive symptoms in patients with treatment-
resistant depression. One study found that a single moderate 
dose of psilocybin in conjunction with psychotherapy 
produced rapid and sustained anxiolytic and anti-depressant 
effects (Ross et al). Another study found that when 
administered under psychologically supportive, double-blind 
conditions, a single dose of psilocybin was able to produce 
clinically significant decreases in depressed mood and 
anxiety along with increase in quality of life for at least six 
months in patients (Griffiths et al). One study concluded that 
patients with both anxious and non-anxious bipolar 
depression had significant antidepressant responses to 
that psychedelics were able to improve depressive 
symptoms.Mental disorder that can be severely debilitating and interfere with one’s 
Overview:

ability to lead a normal life
 Estimated that over 17 million American adults have had at least one 
major depressive episode
Diagnostic Criteria:
 Period of at least two weeks where a person has experienced: 
depressed mood, loss of interest or pleasure in daily activities, loss of 
appetite, abnormal sleep patterns, fatigue, feelings of worthlessness, 
diminished ability to think, recurrent thoughts of death
Treatment:
 Conventional therapies include cognitive behavioral therapy and 
medication classes including SSRI, SNRI, TCA, MAOIs



















6 months Two oral doses of psilocybin (10 

















6 months Psilocybin low dose (1 or 3 
mg/70 kg), high 





































RCT MDD 7 days Ketamine (100mg/ml), 
saline
MADRS
Key: OLT = open label trial, RCT = randomized controlled trial; RS = retrospective study; QIDS-SR16 (QIDS-16) = 16-item 
Quick Inventory of Depressive Symptoms; HADS = Hospital Anxiety and Depression Scale; BDI = Beck Depression 
Inventory; STAI = Spielberger State-Trait Anxiety Inventory; GRID-HAM-D-17 =  clinician-rated measure of depression; 
MADRS = Montgomery-Asberg Depression Rating Scale; HDRS = Hamilton Depression Rating Scale; PTSD = Post-
traumatic Stress Disorder
